Autus Valve
MA - BostonBiotechnology
Focus: Autus Valve is a Boston-based biotech focused on synthetic surgical pulmonary valve replacement for pediatric congenital heart disease. The company is public but very early-stage, founded in 2022 with a single lead program in clinical development.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Autus Valve
AI assessmentNot HiringNo open roles listed right now. Follow Autus Valve to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Autus Valve
Congenital Heart DiseaseClinical Trials (2)
NCT07466745Autus Valve Continued Access Study (CAS)
N/AHelp build intelligence for Autus Valve
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.